Table 1B 2005 Community Prescription Numbers, Together with Government

Total Page:16

File Type:pdf, Size:1020Kb

Table 1B 2005 Community Prescription Numbers, Together with Government TABLE 1B 2005 COMMUNITY PRESCRIPTION NUMBERS, TOGETHER WITH GOVERNMENT AND PATIENT COSTS FOR PBS-LISTED DRUGS Table 1B includes an estimate of community (non-public hospital) prescription numbers for the 2005 calendar year, costs (government and patient contribution) for the items with a four digit PBS/RPBS code, together with the defined daily dose (DDD) where assigned. There is no cost information available for items with a five digit Amfac drug code. Table 1 exclude the presentation of information on any item with an estimated community use of less than 110 prescriptions in 2005. The prescription items are arranged by ATC code on generic name, and by form and strength using either the PBS drug code (4 digit) or, for non-PBS items, the Amfac drug code (5 digit). Consult the index (page 255) by generic drug name to obtain the appropriate ATC code. An index by 2nd level of the ATC classification follows: ALIMENTARY TRACT AND METABOLISM PAGE NO A01 STOMATOLOGICAL PREPARATIONS 181 A02 DRUGS FOR ACID RELATED DISORDERS 182 A03 DRUGS FOR FUNCTIONAL GASTROINTESTINAL DISORDERS 185 A04 ANTIEMETICS AND ANTINAUSEANTS 187 A05 BILE AND LIVER THERAPY 188 A06 LAXATIVES 189 A07 ANTIDIARRHOEALS, INTESTINAL 191 ANTIINFLAMMATORY/ANTIINFECTIVE AGENTS A08 ANTIOBESITY PREPARATIONS, EXCLUDING DIET PRODUCTS 193 A09 DIGESTIVES, INCLUDING ENZYMES 194 A10 DRUGS USED IN DIABETES 195 A11 VITAMINS 197 A12 MINERAL SUPPLEMENTS 199 A14 ANABOLIC AGENTS FOR SYSTEMIC USE 200 177 BLOOD AND BLOOD FORMING ORGANS B01 ANTITHROMBOTIC AGENTS 201 B02 ANTIHAEMORRHAGICS 203 B03 ANTIANAEMIC PREPARATIONS 204 B05 BLOOD SUBSTITUTES AND PERFUSION SOLUTIONS 205 B06 OTHER HAEMATOLOGICAL AGENTS 206 CARDIOVASCULAR SYSTEM C01 CARDIAC THERAPY 207 C02 ANTIHYPERTENSIVES 209 C03 DIURETICS 210 C04 PERIPHERAL VASODILATORS 211 C05 VASOPROTECTIVES 212 C07 BETA BLOCKING AGENTS 213 C08 CALCIUM CHANNEL BLOCKERS 214 C09 AGENTS ACTING ON THE RENIN-ANGIOTENSIN SYSTEM 215 C10 SERUM LIPID REDUCING AGENTS 217 DERMATOLOGICALS D01 ANTIFUNGALS FOR DERMATOLOGICAL USE 218 D02 EMOLLIENTS AND PROTECTIVES 220 D03 PREPARATIONS FOR TREATMENT OF WOUNDS AND ULCERS 221 D04 ANTIPRURITICS, INCLUDING ANTIHISTAMINES, ANAESTHETICS ETC 222 D05 ANTIPSORIATICS 223 D06 ANTIBIOTICS AND CHEMOTHERAPEUTICS FOR DERMATOLOGICAL USE 224 D07 CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS 225 D08 ANTISEPTICS AND DISINFECTANTS 227 D09 MEDICATED DRESSINGS 228 D10 ANTI-ACNE PREPARATIONS 229 D11 OTHER DERMATOLOGICAL PREPARATIONS 230 GENITOURINARY SYSTEM AND SEX HORMONES G01 GYNAECOLOGICAL ANTIINFECTIVES AND ANTISEPTICS 231 G02 OTHER GYNAECOLOGICALS 232 G03 SEX HORMONES AND MODULATORS OF THE GENITAL SYSTEM 233 G04 UROLOGICALS 238 178 SYSTEMIC HORMONAL PREpaRATIONS, EXCL. SEX HORMONES AND INSULINS H01 PITUITARY AND HYPOTHALAMIC HORMONES AND ANALOGUES 239 H02 CORTICOSTEROIDS FOR SYSTEMIC USE 240 H03 THYROID THERAPY 241 H04 PANCREATIC HORMONES 241 H05 CALCIUM HOMEOSTASIS 241 GENERAL ANTIINFECTIVES FOR SYSTEMIC USE J01 ANTIBACTERIALS FOR SYSTEMIC USE 242 J02 ANTIMYCOTICS FOR SYSTEMIC USE 249 J04 ANTIMYCOBACTERIALS 250 J05 ANTIVIRALS FOR SYSTEMIC USE 251 J07 VACCINES 252 ANTINEOPLASTIC AND IMMUNO-MODULATING AGENTS L01 ANTINEOPLASTIC AGENTS 254 L02 ENDOCRINE THERAPY 260 L03 IMMUNOSTIMULANTS 261 L04 IMMUNOSUPPRESSIVE AGENTS 262 MUSCULO-SKELETAL SYSTEM M01 ANTI-INFLAMMATORY AND ANTI-RHEUMATIC PRODUCTS 263 M02 TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN 266 M03 MUSCLE RELAXANTS 267 M04 ANTIGOUT PREPARATIONS 268 M05 DRUGS FOR TREATMENT OF BONE DISEASES 269 NERVOUS SYSTEM N01 ANAESTHETICS 270 N02 ANALGESICS 271 N03 ANTIEPILEPTICS 278 N04 ANTI-PARKINSON DRUGS 281 N05 PSYCHOLEPTICS 283 N06 PSYCHOANALEPTICS 288 N07 OTHER NERVOUS SYSTEM DRUGS 292 ANTIpaRASITIC PRODUCTS, INSECTICIDES AND REPELLENTS P01 ANTIPROTOZOALS 293 P02 ANTHELMINTICS 294 P03 ECTOPARASITICIDES, INCLUDING SCABICIDES, INSECTICIDES AND REPELLENTS 295 179 RESPIRATORY SYSTEM R01 NASAL PREPARATIONS 296 R03 DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES 298 R05 COUGH AND COLD PREPARATIONS 301 R06 ANTIHISTAMINES FOR SYSTEMIC USE 302 SENSORY ORGANS S01 OPHTHALMOLOGICALS 305 S02 OTOLOGICALS 310 S03 OPHTHALMOLOGICAL AND OTOLOGICAL PREPARATIONS 311 VaRIOUS V01 ALLERGENS 312 V03 ALL OTHER THERAPEUTIC PRODUCTS 313 180 A 2005 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($) ALIMENTARY TRACT AND METABOLISM STOMATOLOGICAL PREPARATIONS STOMATOLOGICAL PREPARATIONS ANTIINFECTIVES FOR LOCAL ORAL TREATMENT A01AB04 AMPHOTERICIN 2931 Lozenge 10 mg 40.00 MG 148,722 1,276,858 3306 Lozenge 10 mg 40.00 MG 4,458 37,489 A01AB03 CHLORHEXIDINE 4160 Mouth wash 2 mg per ml (0.2%), 250 ml 30.00 MG 111 1,282 4161 Mouth wash 2 mg per ml (0.2%), 250 ml 30.00 MG 3,205 34,604 A01AB09 MICONAZOLE 13832 Oral gel 20 mg per ml (2%), 20 g 0.20 GM 12,443 – 14054 Oral gel 40 mg per ml (2%), 40 g 0.20 GM 6,003 – A01AB11 NYSTATIN 3033 Oral suspension 100,000 units per ml, 24 ml 1500.00 TE 147,209 1,366,099 3343 Oral suspension 100,000 units per ml, 24 ml 1500.00 TE 1,138 10,386 16261 Pastille 100,000 units 28 – – 653 – A01AB11 POVIDINE IODINE 10359 Gargle 1 – – 197 – A01AB11 THYMOL 11202 Mouth wash red 200ml – – 97 – CORTICOSTEROIDS FOR LOCAL ORAL TREATMENT A01AC01 TRIAMCINOLONE ACETONIDE with PECTIN 11075 Paste 1% 5gm – – 32,081 – OTHER AGENTS FOR LOCAL ORAL TREATMENT A01AD02 BENZYDAMINE HYDROCHLORIDE 1121 Mouth and throat rinse 22.5mg per 15mL,500mL – – 6,720 120,239 5032 Mouth and throat rinse 22.5mg per 15mL – – 59 1,087 13467 Gel 3% 30g 1 – – 232 – 13655 Gel 5% 30g 1 – – 298 – 13757 Gel 3% 75g 1 – – 608 – 14683 Solution 0.15% 200 ml – – 189 – A01AD02 BENZYDAMINE with CHLORHEXIDINE 14358 Solution 100 ml – – 256 – 14359 Solution 200mL – – 49 – A01AD11 CHOLINE SALICYLATE with CETALKONIUM CHLORIDE 12855 Gel 10g 1 – – 3,872 – A01AD11 SALIVA SUBSTITUTE 4568 Solution 25 ml – – 312 2,586 4569 Solution 100 ml – – 665 9,107 A01AD11 VARIOUS 5334 Spray 10mg per mL, 100 mL – – 236 2,543 181 A 2005 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($) ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS ANTACIDS ALUMINIUM COMPOUNDS A02AB01 ALUMINIUM HYDROXIDE 10038 Tablet 600 mg 100 – – 786 – CALCIUM COMPOUNDS A02AC10 CALCIUM CARBONATE with GLYCINE 4055 Tablet 420 mg-180 mg – – 566 10,776 COMBS AND COMPLEXES OF ALUMINIUM,CALCIUM AND MAGNESIUM COMPOUNDS A02AD ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE 2157 Oral suspension 200 mg-200 mg per 5 ml, 500 ml – – 59,444 746,589 2576 Tablet 200 mg-200 mg – – 49,358 614,705 4117 Tablet 400 mg-400 mg-30 mg – – 3,478 82,381 4118 Oral suspension 400 mg-400 mg-30 mg per 5 ml, – – 1,970 36,289 A02AD ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE with SIMETHICONE 11195 Table (chewable) 50 – – 122 – 11196 Mixture 750ml 1 – – 138 – A02AD ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE with SIMETHICONE with SORBITOL 11225 Table (chewable) 50 – – 158 – A02AD ALUMINIUM HYDROXIDE with MAGNESIUM TRISILICATE and MAGNESIUM HYDROXIDE 2159 Oral suspension 250 mg-120 mg-120 mg per 5 ml, – – 39,841 497,156 18762 Tablet 250 mg-120 mg-120 mg – – 243 – ANTACIDS, OTHER COMBINATIONS A02AX ALUMINIUM HYDROXIDE with MAGNESIUM HYDROXIDE with OXETHAZAINE 16009 Mixture 500ml 1 – – 875 – DRUGS FOR PEPTIC ULCER AND GORD H2-RECEPTOR ANTAGONISTS A02BA01 CIMETIDINE 1156 Effervescent tablet 800 mg (as hydrochloride) 0.80 GM 2,715 74,834 1157 Tablet 200 mg 0.80 GM 4,431 119,472 1158 Tablet 400 mg 0.80 GM 40,119 1,093,524 1159 Tablet 800 mg 0.80 GM 6,495 181,385 8901 Effervescent tablet 800 mg (as hydrochloride) 0.80 GM 271 11,748 A02BA03 FAMOTIDINE 2487 Tablet 20 mg 40.00 MG 112,016 2,388,087 2488 Tablet 40 mg 40.00 MG 101,509 2,299,267 A02BA04 NIZATIDINE 1504 Capsules 300mg 30 0.30 GM 25,810 614,262 1505 Capsules 150mg 30 0.30 GM 84,097 1,913,414 4967 Capsules 150mg 60 0.30 GM 174 4,476 4969 Capsules 300mg 30 0.30 GM 64 2,370 8931 Capsules 150mg 60 0.30 GM 970 25,235 8933 Capsules 300mg 30 0.30 GM 300 11,045 A02BA02 RANITIDINE HYDROCHLORIDE 1937 Effervescent tablet 150 mg (base) 0.30 GM 55,434 1,215,991 1977 Tablet 300 mg (base) 0.30 GM 313,986 7,095,599 1978 Tablet 150 mg (base) 0.30 GM 1,119,067 24,541,469 4978 Effervescent tablet 150 mg (base) 0.30 GM 500 12,472 4980 Syrup 150 mg (base) per 10 ml, 300 ml 0.30 GM 709 17,173 8162 Syrup 150 mg (base) per 10 ml, 300 ml 0.30 GM 18,742 370,539 8903 Effervescent tablet 150 mg (base) 0.30 GM 1,463 37,492 8905 Syrup 150 mg (base) per 10 ml, 300 ml 0.30 GM 443 13,653 17164 Tablet 150 mg 14 0.30 GM 316 – 182 A 2005 ATC CODE FORM AND STRENGTH DDD UNITS SCRIPTS COST($) ALIMENTARY TRACT AND METABOLISM DRUGS FOR ACID RELATED DISORDERS DRUGS FOR PEPTIC ULCER AND GORD PROSTAGLANDINS A02BB01 MISOPROSTOL 1648 Tablet 200 ug 0.80 MG 2,665 137,892 PROTON PUMP INHIBITORS A02BC05 ESOMEPRAZOLE 8600 Tablet 20 mg (enteric coated),30 30.00 MG 2,067,514 95,698,661 8601 Tablet 40 mg (enteric coated),30 30.00 MG 1,294,189 97,535,964 A02BC03 LANSOPRAZOLE 2240 Capsule 30 mg 30.00 MG 37,445 1,732,847 2241 Capsule 30 mg 30.00 MG 818,805 40,470,231 8198 Capsule 15 mg 30.00 MG 22,099 645,393 8528 Sachet for oral suspension, 30mg 30.00 MG 3,448 147,962 8529 Sachet for oral suspension, 30mg 30.00 MG 16,763 751,065 A02BC01 OMEPRAZOLE 1326 Capsule 20 mg 20.00 MG 20,675 801,170 1327 Capsule 20 mg 20.00 MG 203,625 9,613,825 8331 Tablet 20mg (base) 30 20.00 MG 149,101 6,437,686 8332 Tablet 10 mg 30 20.00 MG 57,017 1,697,342 8333 Tablet 20 mg 30 20.00 MG 3,866,360 183,135,279 8776 Tablet 20 mg 30 20.00 MG 2,447 105,012 8777 Tablet 20 mg 30 20.00 MG 23,458 1,070,636 15213 Vial 40 mg 10 ml 5 20.00 MG 483 – A02BC02 PANTOPRAZOLE 8007 Tablet (enteric coated) equivalent to 40mg 40.00 MG 258,470 12,102,901 8008 Tablet
Recommended publications
  • The Impact of a Changed Legislation on Reporting of Adverse Drug Reactions in Sweden, with Focus on Nurses Reporting
    The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses reporting Sofia A. Karlsson, Ingela Jacobsson, Marit Danell Boman, Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg and Anna K Jönsson Linköping University Post Print N.B.: When citing this work, cite the original article. The original publication is available at www.springerlink.com: Sofia A. Karlsson, Ingela Jacobsson, Marit Danell Boman, Katja M. Hakkarainen, Henrik Lövborg, Staffan Hägg and Anna K Jönsson, The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses reporting, 2015, European Journal of Clinical Pharmacology, (71), 5, 631-636. http://dx.doi.org/10.1007/s00228-015-1839-6 Copyright: Springer Verlag (Germany) http://www.springerlink.com/?MUD=MP Postprint available at: Linköping University Electronic Press http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-118037 The impact of a changed legislation on reporting of adverse drug reactions in Sweden, with focus on nurses’ reporting Sofia A Karlsson1, Ingela Jacobsson2, Marit Danell Boman3, Katja M Hakkarainen4,5, Henrik Lövborg2, Staffan Hägg2,5, Anna K Jönsson2 Affiliations: 1. Department of Public Health and Community Medicine, the Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden 2. Department of Clinical Pharmacology and Department of Medical and Health Sciences, Linköping University, Linköping, Sweden 3. Division of Clinical Pharmacology, University Hospital of Umeå, Umeå, Sweden 4. Nordic School of
    [Show full text]
  • Crohn's & Colitis Program, Patient Information Guide
    Inflammatory Bowel Disease Program Patient Information Guide Page # Contents ..........................................................................................................................................1 Welcome! Welcome Letter ....................................................................................................................3 Important Things to Know Up Front ....................................................................................4 Meet Your Crohn’s & Colitis Team .....................................................................................6 How to Contact Us Crohn’s & Colitis Clinic Schedule .....................................................................................11 Physician and Nurse Contact Information..........................................................................12 Appointment Scheduling and Other Contact Information..................................................13 The Basics of Inflammatory Bowel Disease (IBD) Basic Information about Inflammatory Bowel Disease (IBD) ...........................................14 Frequently Asked Questions about Inflammatory Bowel Disease (IBD) ..........................18 Testing in IBD Colonoscopy and Flexible Sigmoidoscopy ........................................................................20 Upper Endoscopy ...............................................................................................................21 Capsule Endoscopy and Deep Enteroscopy .......................................................................22
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group R01 (Nasal preparations) Table of Contents Page INTRODUCTION 5 DISCLAIMER 7 GLOSSARY OF TERMS USED IN THIS DOCUMENT 8 ACTIVE SUBSTANCES Cyclopentamine (ATC: R01AA02) 10 Ephedrine (ATC: R01AA03) 11 Phenylephrine (ATC: R01AA04) 14 Oxymetazoline (ATC: R01AA05) 16 Tetryzoline (ATC: R01AA06) 19 Xylometazoline (ATC: R01AA07) 20 Naphazoline (ATC: R01AA08) 23 Tramazoline (ATC: R01AA09) 26 Metizoline (ATC: R01AA10) 29 Tuaminoheptane (ATC: R01AA11) 30 Fenoxazoline (ATC: R01AA12) 31 Tymazoline (ATC: R01AA13) 32 Epinephrine (ATC: R01AA14) 33 Indanazoline (ATC: R01AA15) 34 Phenylephrine (ATC: R01AB01) 35 Naphazoline (ATC: R01AB02) 37 Tetryzoline (ATC: R01AB03) 39 Ephedrine (ATC: R01AB05) 40 Xylometazoline (ATC: R01AB06) 41 Oxymetazoline (ATC: R01AB07) 45 Tuaminoheptane (ATC: R01AB08) 46 Cromoglicic Acid (ATC: R01AC01) 49 2 Levocabastine (ATC: R01AC02) 51 Azelastine (ATC: R01AC03) 53 Antazoline (ATC: R01AC04) 56 Spaglumic Acid (ATC: R01AC05) 57 Thonzylamine (ATC: R01AC06) 58 Nedocromil (ATC: R01AC07) 59 Olopatadine (ATC: R01AC08) 60 Cromoglicic Acid, Combinations (ATC: R01AC51) 61 Beclometasone (ATC: R01AD01) 62 Prednisolone (ATC: R01AD02) 66 Dexamethasone (ATC: R01AD03) 67 Flunisolide (ATC: R01AD04) 68 Budesonide (ATC: R01AD05) 69 Betamethasone (ATC: R01AD06) 72 Tixocortol (ATC: R01AD07) 73 Fluticasone (ATC: R01AD08) 74 Mometasone (ATC: R01AD09) 78 Triamcinolone (ATC: R01AD11) 82
    [Show full text]
  • (12) STANDARD PATENT (11) Application No. AU 2015336929 B2 (19) AUSTRALIAN PATENT OFFICE
    (12) STANDARD PATENT (11) Application No. AU 2015336929 B2 (19) AUSTRALIAN PATENT OFFICE (54) Title Methods of reducing mammographic breast density and/or breast cancer risk (51) International Patent Classification(s) A61K 31/568 (2006.01) A61K 31/585 (2006.01) A61K 31/4196 (2006.01) A61P 35/00 (2006.01) A61K 31/5685 (2006.01) A61P 43/00 (2006.01) (21) Application No: 2015336929 (22) Date of Filing: 2015.10.22 (87) WIPO No: W016/061615 (30) Priority Data (31) Number (32) Date (33) Country 62/067,297 2014.10.22 US (43) Publication Date: 2016.04.28 (44) Accepted Journal Date: 2021.03.18 (71) Applicant(s) Havah Therapeutics Pty Ltd (72) Inventor(s) Birrell, Stephen Nigel (74) Agent / Attorney Adams Pluck, Suite 4, Level 3 20 George Street, Hornsby, NSW, 2077, AU (56) Related Art WO 2002/009721 Al MOUSA, N.A. et al. "Aromatase inhibitors and mammographic breast density in postmenopausal women receiving hormone therapy" Menopause: The Journal of The North American Menopause Society (2008) Vol.15 No.5, pages 875 to 884 WO 2009/036566 Al SMITH, J. et al. "A Pilot Study of Letrozole for One Year in Women at Enhanced Risk of Developing Breast Cancer: Effects on Mammographic Density" Anticancer Research (2012) Vol.32 No.4, pages 1327 to 1332 OUIMET-OLIVA, D. et al. Canadian Association of Radiologists Journal (1981) Vol.32 No.3, pages 159 to 161 (see online PubMed Abstract PMID: 7298699) (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International
    [Show full text]
  • Complementary and Alternative Treatments for Alopecia: a Comprehensive Review
    Review Article Skin Appendage Disord 2019;5:72–89 Received: April 22, 2018 DOI: 10.1159/000492035 Accepted: July 10, 2018 Published online: August 21, 2018 Complementary and Alternative Treatments for Alopecia: A Comprehensive Review Anna-Marie Hosking Margit Juhasz Natasha Atanaskova Mesinkovska Department of Dermatology, University of California, Irvine, Irvine, CA, USA Keywords Introduction Alopecia · Complementary and alternative medicine · Efficacy According to the National Center for Complementary and Integrative Health (NCCIH), a branch of the Nation- al Institutes of Health (NIH; Bethesda, MD, USA), more Abstract than 30% of adults and 12% of children utilize treatments The treatment of alopecia is limited by a lack of therapies developed “outside of mainstream Western, or conven- that induce and sustain disease remission. Given the nega- tional, medicine,” with a total USD 30.2 billion out-of- tive psychosocial impact of hair loss, patients that do not pocket dollars spent annually [1]. In the treatment of alo- see significant hair restoration with conventional therapies pecia, there is an unmet need for therapies providing sat- often turn to complementary and alternative medicine isfying, long-term results. Patients often turn to (CAM). Although there are a variety of CAM treatment op- complementary and alternative medicine (CAM) in an tions on the market for alopecia, only a few are backed by attempt to find safe, natural, and efficacious therapies to multiple randomized controlled trials. Further, these mo- restore hair. Although CAMs boast hair-growing poten- dalities are not regulated by the Food and Drug Administra- tial, patients may be disappointed with results as there is tion and there is a lack of standardization of bioactive in- a lack of standardization of bioactive ingredients and lim- gredients in over-the-counter vitamins, herbs, and supple- ited scientific evidence.
    [Show full text]
  • Characterising the Risk of Major Bleeding in Patients With
    EU PE&PV Research Network under the Framework Service Contract (nr. EMA/2015/27/PH) Study Protocol Characterising the risk of major bleeding in patients with Non-Valvular Atrial Fibrillation: non-interventional study of patients taking Direct Oral Anticoagulants in the EU Version 3.0 1 June 2018 EU PAS Register No: 16014 EMA/2015/27/PH EUPAS16014 Version 3.0 1 June 2018 1 TABLE OF CONTENTS 1 Title ........................................................................................................................................... 5 2 Marketing authorization holder ................................................................................................. 5 3 Responsible parties ................................................................................................................... 5 4 Abstract ..................................................................................................................................... 6 5 Amendments and updates ......................................................................................................... 7 6 Milestones ................................................................................................................................. 8 7 Rationale and background ......................................................................................................... 9 8 Research question and objectives .............................................................................................. 9 9 Research methods ....................................................................................................................
    [Show full text]
  • Annex D to the Report of the Panel to Be Found in Document WT/DS320/R
    WORLD TRADE WT/DS320/R/Add.4 31 March 2008 ORGANIZATION (08-0902) Original: English UNITED STATES – CONTINUED SUSPENSION OF OBLIGATIONS IN THE EC – HORMONES DISPUTE Report of the Panel Addendum This addendum contains Annex D to the Report of the Panel to be found in document WT/DS320/R. The other annexes can be found in the following addenda: – Annex A: Add.1 – Annex B: Add.2 – Annex C: Add.3 – Annex E: Add.5 – Annex F: Add.6 – Annex G: Add.7 WT/DS320/R/Add.4 Page D-1 ANNEX D REPLIES OF THE SCIENTIFIC EXPERTS TO QUESTIONS POSED BY THE PANEL A. GENERAL DEFINITIONS 1. Please provide brief and basic definitions for the six hormones at issue (oestradiol-17β, progesterone, testosterone, trenbolone acetate, zeranol, and melengestrol acetate), indicating the source of the definition where applicable. Dr. Boisseau 1. Oestradiol-17β is the most active of the oestrogens hormone produced mainly by the developing follicle of the ovary in adult mammalian females but also by the adrenals and the testis. This 18-carbon steroid hormone is mainly administered as such or as benzoate ester alone (24 or 45 mg for cattle) or in combination (20 mg) with testosterone propionate (200 mg for heifers), progesterone (200 mg for heifers and steers) and trenbolone (200 mg and 40 mg oestradiol-17β for steers) by a subcutaneous implant to the base of the ear to improve body weight and feed conversion in cattle. The ear is discarded at slaughter. 2. Progesterone is a hormone produced primarily by the corpus luteum in the ovary of adult mammalian females.
    [Show full text]
  • Initial Proposed Smpc Plus Proposed Revisions
    1. NAME OF THE MEDICINAL PRODUCT Leticia 28 150 micrograms/30 microgram film-coated tablet 2. QUALITATIVE AND QUANTITATIVE COMPOSITION 21 white or almost white film-coated tablets: Each film-coated tablet contains 150 micrograms desogestrel 30 micrograms ethinylestradiol. Excipient with known effect: 64.3 mg lactose (as lactose monohydrate). 7 green placebo (inactive) film-coated tablets: The tablet does not contain active substances. Excipients with known effect: 37.26 mg lactose anhydrous and 0.003 mg sunset yellow. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet. The active tablet is white, or almost white, round shaped, biconvex film-coated tablets of 6 mm diameter, with P8 sign on one side and RG sign on other side. The placebo tablet is green, round, biconvex film-coated tablet, diameter about 6 mm, without engraving. 4. CLINICAL PARTICULARS 4.1 Therapeutic indications Oral contraception The decision to prescribe Leticia 28 should take into consideration the individual woman’s current risk factors, particularly those for venous thromboembolism (VTE), and how the risk of VTE with Leticia 28 compares with other combined hormonal contraceptives (CHCs) (see sections 4.3 and 4.4). 4.2 Posology and method of administration Posology How to take Leticia 28 The tablets must be taken in the order directed on the package every day at about the same time of the day. Tablet taking is continuous. One tablet is taken daily for 28 consecutive days. Each subsequent pack is started after the last tablet of the previous pack. During the intake of the 7 placebo tablets bleeding usually occurs.
    [Show full text]
  • Inflammatory Bowel Disease Agents
    Therapeutic Class Overview Inflammatory Bowel Disease Agents INTRODUCTION • Inflammatory bowel disease (IBD) is a spectrum of chronic idiopathic inflammatory intestinal conditions that cause gastrointestinal symptoms including diarrhea, abdominal pain, bleeding, fatigue, and weight loss. The exact cause of IBD is unknown; however, proposed etiologies involve a combination of infectious, genetic, and lifestyle factors (Bernstein et al 2015, Peppercorn 2019[a], Peppercorn 2020[c]). • Complications of IBD include hemorrhage, rectal fissures, fistulas, peri-rectal and intra-abdominal abscesses, and colon cancer. Possible extra-intestinal complications include hepatobiliary complications, anemia, arthritis and arthralgias, uveitis, skin lesions, and mood and anxiety disorders (Bernstein et al 2015). • Ulcerative colitis (UC) and Crohn’s disease (CD) are 2 forms of IBD that differ in pathophysiology and presentation; as a result of these differences, the approach to the treatment of each condition often differs (Peppercorn 2019[a]). • UC is characterized by recurrent episodes of inflammation of the mucosal layer of the colon. The inflammation, limited to the mucosa, commonly involves the rectum and may extend in a proximal and continuous fashion to affect other parts of the colon. The hallmark clinical symptom is an inflamed rectum with symptoms of urgency, bleeding, and tenesmus (Peppercorn 2020[c], Rubin et al 2019). • CD can involve any part of the gastrointestinal tract and is characterized by transmural inflammation and “skip areas.” Transmural inflammation may lead to fibrosis, strictures, sinus tracts, and fistulae (Peppercorn 2019[b]). • The immune system is known to play a critical role in the underlying pathogenesis of IBD. It is suggested that abnormal responses of both innate and adaptive immunity mechanisms induce aberrant intestinal tract inflammation in IBD patients (Geremia et al 2014).
    [Show full text]
  • Assessing the Availability, Service Quality, and Price of Essential Medicines In
    Assessing the Availability, Service Quality, and Price of Essential Medicines in Private Pharmacies in Afghanistan Norio Kasahara A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy University of Washington 2015 Reading Committee: Louis P. Garrison, Jr., Chair Joseph B. Babigumira Andy Stergachis Program Authorized to Offer Degree: Pharmaceutical Outcomes Research and Policy ©Copyright 2015 Norio Kasahara ii Table of Contents Abstract ................................................................................................................................................................................... ................................................................................................ ................................................................................................ .................................................................................. ............... vvv Acknowledgements ................................................................................................................................................................................... ................................................................................................ ................................................................................. ............ viiviivii Summary ................................................................................................................................................................................... ...............................................................................................
    [Show full text]
  • WO 2014/167554 A2 16 October 2014 (16.10.2014) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2014/167554 A2 16 October 2014 (16.10.2014) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every A61K 47/10 (2006.01) kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, (21) International Application Number: BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, PCT/IB20 14/060675 DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, (22) International Filing Date: HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, 12 April 2014 (12.04.2014) KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (25) Filing Language: English OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (26) Publication Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, (30) Priority Data: zw. 1103/DEL/2013 12 April 2013 (12.04.2013) IN (84) Designated States (unless otherwise indicated, for every (71) Applicant: VYOME BIOSCIENCES PVT. LTD. kind of regional protection available): ARIPO (BW, GH, [IN/IN]; 459 F.I.E, First Floor, Patparganj Industrial Area, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, New Delhi 110092 (IN).
    [Show full text]
  • Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy Using Machine Learning
    Prediction of Premature Termination Codon Suppressing Compounds for Treatment of Duchenne Muscular Dystrophy using Machine Learning Kate Wang et al. Supplemental Table S1. Drugs selected by Pharmacophore-based, ML-based and DL- based search in the FDA-approved drugs database Pharmacophore WEKA TF 1-Palmitoyl-2-oleoyl-sn-glycero-3- 5-O-phosphono-alpha-D- (phospho-rac-(1-glycerol)) ribofuranosyl diphosphate Acarbose Amikacin Acetylcarnitine Acetarsol Arbutamine Acetylcholine Adenosine Aldehydo-N-Acetyl-D- Benserazide Acyclovir Glucosamine Bisoprolol Adefovir dipivoxil Alendronic acid Brivudine Alfentanil Alginic acid Cefamandole Alitretinoin alpha-Arbutin Cefdinir Azithromycin Amikacin Cefixime Balsalazide Amiloride Cefonicid Bethanechol Arbutin Ceforanide Bicalutamide Ascorbic acid calcium salt Cefotetan Calcium glubionate Auranofin Ceftibuten Cangrelor Azacitidine Ceftolozane Capecitabine Benserazide Cerivastatin Carbamoylcholine Besifloxacin Chlortetracycline Carisoprodol beta-L-fructofuranose Cilastatin Chlorobutanol Bictegravir Citicoline Cidofovir Bismuth subgallate Cladribine Clodronic acid Bleomycin Clarithromycin Colistimethate Bortezomib Clindamycin Cyclandelate Bromotheophylline Clofarabine Dexpanthenol Calcium threonate Cromoglicic acid Edoxudine Capecitabine Demeclocycline Elbasvir Capreomycin Diaminopropanol tetraacetic acid Erdosteine Carbidopa Diazolidinylurea Ethchlorvynol Carbocisteine Dibekacin Ethinamate Carboplatin Dinoprostone Famotidine Cefotetan Dipyridamole Fidaxomicin Chlormerodrin Doripenem Flavin adenine dinucleotide
    [Show full text]